Hemostemix (CVE:HEM) Trading Up 30% – What’s Next?

Hemostemix Inc. (CVE:HEM) shares shot up 30% during mid-day trading on Tuesday . The company traded as high as C$0.15 and last traded at C$0.13. 430,289 shares traded hands during trading, a decline of 10% from the average session volume of 480,285 shares. The stock had previously closed at C$0.10.

Hemostemix Stock Up 30.0%

The firm has a market capitalization of C$18.94 million, a price-to-earnings ratio of -3.79 and a beta of 0.20. The business has a 50 day moving average of C$0.10 and a 200 day moving average of C$0.14. The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48.

Insider Buying and Selling at Hemostemix

In other Hemostemix news, Director Peter Alan Lacey acquired 200,000 shares of Hemostemix stock in a transaction dated Thursday, March 6th. The stock was bought at an average cost of C$0.15 per share, with a total value of C$30,000.00. Insiders own 10.43% of the company’s stock.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.